Patients with CFC harbor activating missense variants in BRAF (MIM#115150), MAP2K1 (MIM#615279), MAP2K2 (MIM#615280), and KRAS (MIM#615278), most of which are de novo variants [2]. Here, KRAS is linked to cardiofaciocutaneous syndrome.